ExodusPoint Capital Management’s Enliven Therapeutics ELVN Stock Holding History

ExodusPoint Capital Management’s Portfolio ELVN Stock Details ELVN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.18M	Sell	30,101 -30,314	-50%	-$840K	0.01%	949
2025 Q4	$930K	Buy	60,415 +12,280	+26%	+$245K	0.01%	1022
2025 Q3	$985K	Buy	+48,135	New	+$970K	0.01%	963
2025 Q2	–	Sell	-33,984	Closed	-$669K	–	1592
2025 Q1	$669K	Buy	33,984 +25,084	+282%	+$540K	0.01%	1036
2024 Q4	$200K	Buy	+8,900	New	+$231K	﹤0.01%	1364
2020 Q2	–	Sell	-4,957	Closed	-$318K	–	1831
2020 Q1	$318K	Buy	+4,957	New	+$316K	0.02%	636

Other funds holding ELVN

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

ExodusPoint Capital Management's ELVN Position: Q1 2026 in Review

ExodusPoint Capital Management reduced its Enliven Therapeutics (ELVN) stake by 50% in Q1 2026, selling an estimated $840K and leaving 30,101 shares worth $1.18M. The position accounts for 0.01% of the portfolio, ranked #949.

ExodusPoint Capital Management first reported a position in ELVN in Q1 2020 and has held it in 6 quarters since. 170 funds tracked by Wall St. Rank hold ELVN as of Q1 2026.

ExodusPoint Capital Management held 30,101 shares of Enliven Therapeutics worth $1.18M as of Q1 2026.
ExodusPoint Capital Management sold 30,314 Enliven Therapeutics shares in Q1 2026, an estimated $840K.
Enliven Therapeutics made up 0.01% of ExodusPoint Capital Management's portfolio in Q1 2026, its #949 holding.
ExodusPoint Capital Management first reported a position in Enliven Therapeutics in Q1 2020 and has held it in 6 quarters since.
170 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q1 2026.

Based on ExodusPoint Capital Management's 13F filing for Q1 2026, filed 14 May 2026.